U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H21N5O4
Molecular Weight 311.3369
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of XANTHINOL

SMILES

CN(CCO)CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C

InChI

InChIKey=DSFGXPJYDCSWTA-UHFFFAOYSA-N
InChI=1S/C13H21N5O4/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2/h8-9,19-20H,4-7H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C13H21N5O4
Molecular Weight 311.3369
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Xanthinol (xanthinol nicotinate) is a xanthine derivative, peripheral vasodilator agent. It exerts it`s pharmacological action by acting as a vasodilator and improves blood flow to brain, arteries, and to the periphery. It increases brain glucose metabolism and thus improves brain ATP levels. It stimulates memory and concentration elevates brain energy levels. Indications for Xanthinol Nicotinate: 1. Peripheral vascular sclerosis 2. Cerebral circulatory disorders 3. Arteriosclerosis 4. Endarteritis obliterans 5. Short term memory disorders 6. Mental flagging 7. Anti ageing memory support 8. Diabetic angiopathy 9. Diabetic gangrene 10. Hyperlipidaemia 11. Intermittent claudication Side Effects of Xanthinol Nicotinate: 1. Flushing 2. Feeling of warmth 3. Nausea 4. Heart burn 5. Vomiting 6. Itching of skin For 30 years, Xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. Xanthinol nicotinate is also helpful in the management of leg ulcers associated with haemoglobinopathies. Xanthinol was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. The positively charged xanthinol ion is thought to help the transportation of the nicotinic acid into the cell since the later cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to present influence in the cell metabolism through the nucleotides NAD and NADP. Also, the nicotinic acid is a coenzyme for a lot of proteins involved in tissue respiration (Embden-Meyerhof and citrate cycle). The effect of xanthinol nicotinate causes an increase in glucose metabolism and energy gain.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Complamin

Approved Use

Xanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions.
Primary
Complamin

Approved Use

Xanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions.

Launch Date

1992
PubMed

PubMed

TitleDatePubMed
Psoriasis and side-effects of mesotherapy.
2001 Sep
[Pathogenetic basis for using prodectin and teonicol, redergin and aescuzan in complex treatment of chronic gastritis].
2002
[Sudden hearing loss--our experience in treatment with vasoactive therapy].
2008 Mar-Apr
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets.
2008 Sep 15
Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.
2009
Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors.
2010 Jan 15
[Peyronie's disease: comparative results of conservative treatment].
2010 Nov-Dec

Sample Use Guides

Typical Dosage for Xanthinol Nicotinate Oral: 300mg 8th hourly. Increases the dosage up to 600mg 8th hourly if required. Maximum dose: 1800mg/day. I.V. or I.M.: 300mg. Maximum dose: 900mg.
Route of Administration: Other
HUASMCs were treated with different concentrations of Xanthinol (xanthinol nicotinate) (0, 2.76, 27.6 or 276 uM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:26:21 GMT 2023
Edited
by admin
on Sat Dec 16 01:26:21 GMT 2023
Record UNII
TN1B5910V2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
XANTHINOL
Systematic Name English
XANTINOL
Common Name English
Code System Code Type Description
RXCUI
89795
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY RxNorm
EVMPD
SUB126903
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
PUBCHEM
9913
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
SMS_ID
100000153088
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
DRUG BANK
DB09092
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
FDA UNII
TN1B5910V2
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
DRUG CENTRAL
4368
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
WIKIPEDIA
Xanthinol
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048255
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
CAS
2530-97-4
Created by admin on Sat Dec 16 01:26:21 GMT 2023 , Edited by admin on Sat Dec 16 01:26:21 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY